Green, Rebecca E.
Lord, Jodie
Scelsi, Marzia A.
Xu, Jin
Wong, Andrew
Naomi-James, Sarah
Handy, Alex
Gilchrist, Lachlan
Williams, Dylan M.
Parker, Thomas D.
Lane, Christopher A.
Malone, Ian B.
Cash, David M.
Sudre, Carole H.
Coath, William
Thomas, David L.
Keuss, Sarah
Dobson, Richard
Legido-Quigley, Cristina
Fox, Nick C.
Schott, Jonathan M.
Richards, Marcus
Proitsi, Petroula
,
Article History
Received: 15 September 2022
Accepted: 8 February 2023
First Online: 22 February 2023
Declarations
:
: Ethical approval was obtained from the National Research Ethics Service Committee London (14/LO/1173). The study was conducted in accordance with the Declaration of Helsinki, and all participants provided written informed consent.
: Not applicable.
: MAS is currently a full-time employee of F. Hoffman-La Roche AG. However, her contributions to this research precede in time and are unrelated to her present employment. J.M.S. has received research funding from Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly), has consulted for Roche Pharmaceuticals, Biogen, Merck, and Eli Lilly, given educational lectures sponsored by GE Healthcare, Eli Lilly, and Biogen. He is Clinical Advisor to UK DRI and Chief Medical Officer for ARUK.